HIV-1抗原扩增特异性T细胞疗法联合伏立诺他对接受抗逆转录病毒治疗的HIV感染者持续性HIV-1感染的影响
6例HIV感染者接受2×10^7 HXTCs/m²联合伏立诺他400mg,3例接受10×10^7 HXTCs/m²联合伏立诺他。治疗安全且检测到伏立诺他系列效应生物标志物,但循环细胞中未见增强的抗病毒活性。部分感染者QVOA下降,但多数未超过6倍阈值。
要点
- 伏立诺他联合HIV特异性T细胞疗法安全,并检测到伏立诺他系列效应生物标志物。
- 2×10^7 HXTCs/m²联合伏立诺他组6例中1例QVOA下降,10×10^7 HXTCs/m²组3例均下降。
- 多数QVOA下降未超过6倍阈值,不足以明确归因于研究干预。
核心结论
- 这些 modest 效应支持HIV潜伏逆转和储存库清除策略,但需要更有效的干预来实现持续性HIV的深度清除,从而可能产生临床获益。
研究设计与样本
- 6例接受抗逆转录病毒治疗的HIV感染者接受2×10^7 HXTCs/m²联合伏立诺他400mg输注,3例接受10×10^7 HXTCs/m²联合伏立诺他输注。
- 通过包括静息CD4+ T细胞定量病毒生长试验(QVOA)在内的多种检测方法,测量研究治疗前后持续性HIV的频率。
主要发现
- 伏立诺他和HXTCs安全,检测到伏立诺他系列效应生物标志物,但循环细胞中未见增强的抗病毒活性。
- 2×10^7 HXTCs/m²联合伏立诺他组6例中1例QVOA下降;10×10^7 HXTCs/m²联合伏立诺他组3例均出现QVOA下降。
- 多数下降未超过明确归因于研究干预所需的6倍阈值。
局限性
- 多数QVOA下降未超过明确归因于研究干预所需的6倍阈值。
- 需要更有效的干预来实现持续性HIV的深度清除,从而可能产生临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The histone deacetylase inhibitor vorinostat (VOR) can reverse human immunodeficiency virus type 1 (HIV-1) latency in vivo and allow T cells to clear infected cells in vitro. HIV-specific T cells (HXTCs) can be expanded ex vivo and have been safely administered to people with HIV (PWH) on antiretroviral therapy. METHODS: Six PWH received infusions of 2 × 107 HXTCs/m² with VOR 400 mg, and 3 PWH received infusions of 10 × 107 HXTCs/m² with VOR. The frequency of persistent HIV by multiple assays including quantitative viral outgrowth assay (QVOA) of resting CD4+ T cells was measured before and after study therapy. RESULTS: VOR and HXTCs were safe, and biomarkers of serial VOR effect were detected, but enhanced antiviral activity in circulating cells was not evident. After 2 × 107 HXTCs/m² with VOR, 1 of 6 PWH exhibited a decrease in QVOA, and all 3 PWH exhibited such declines after 10 × 107 HXTCs/m² and VOR. However, most declines did not exceed the 6-fold threshold needed to definitively attribute decline to the study intervention. CONCLUSIONS: These modest effects provide support for the strategy of HIV latency reversal and reservoir clearance, but more effective interventions are needed to yield the profound depletion of persistent HIV likely to yield clinical benefit. Clinical Trials Registration. NCT03212989.
引用
- Gay CL, Hanley PJ, Falcinelli SD, et al. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy. J Infect Dis. 2024. PMID: 38349333. doi:10.1093/infdis/jiad423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。